TABLE 7.

Actual antigenemia quantitation assay-guided treatment and predicted NASBA-guided treatment with respect to median antigenemia levels in the two major groups of differentially treated patients

NASBA result	No. of patients (median [range] antigenemia level) treated under guidance of
	Antigenemia quantitation assay (actual treatment)		NASBA (predicted treatment)
	SOTRs with reactivations (n = 20)	BMTRs and SOTRs with primary infections (n = 19)	SOTRs with reactivations (n = 20)	BMTRs and SOTRs with primary infections (n = 19)
Positive	8 (87 [3–580])a	14 (13.5 [1–270])b	15 (16 [0–124])c	14 (9 [0–110])d
Negative	1 (1)e	5 (2 [1–4])f	0	0
Total	9	19	15	14

^aFour patients started treatment because of a median antigenemia level of 158 (range, 124 to 580), and four started treatment because of a rejection episode with a median antigenemia level of 20.5 (range, 3 to 50). 

^bNine patients were BMTRs with a median antigenemia level of 18 (range, 4 to 105), and five were SOTRs with primary infections with a median antigenemia level of 9 (range, 1 to 270). 

^cUpon NASBA positivity, the eight patients treated under antigenemia quantitation assay guidance had a median antigenemia level of 44.5 (range, 6 to 124), and the seven additional patients had a median antigenemia level of 5 (range, 0 to 38). 

^dUpon NASBA positivity, among the same group of 14 patients treated under antigenemia quantitation assay guidance, the 9 BMTRs had a median antigenemia level of 11 (range, 1 to 110) and the 5 SOTRs with primary infections had a median antigenemia level of 7 (range, 0 to 100). 

^eLTR treated because of rejection. 

^fAll BMTRs.